To validate the findings of Sandmann et al. [23], in which IDH1 WT proneural glioblastoma may derive an OS benefit from first-line bevacizumab treatment, we applied the gene expression classification with mesenchymal, proliferative, and proneural subtypes proposed by Phillips et al. [31] using NanoString technology [3]. The gene discussed is IDH1; the disease is glioblastoma.